Drug Development Strategy, Clinical Trials, Team Effectiveness
Janske is a physician-scientist and former Pfizer executive with two decades of experience leading development programs across multiple therapeutic areas. She brings an end-to-end understanding of clinical, regulatory, and medical functions, with a proven record of delivering inspection-ready programs and global submissions. She now applies her expertise in agile, mission-driven environments, helping biotech and life-science ventures design robust clinical paths, strengthen cross-functional execution, and build trust with investors, partners, and regulators.
Expertise
- Drug development strategy from IND to registration
- Clinical trial design, trial rescue and de-risking
- Cross-functional leadership and team effectiveness
- Co-development frameworks and partner communications
- Global medical affairs and evidence generation
Experience
- Led mid- to late-stage programs in Inflammation & Immunology, Rare Disease, Cardio-Metabolic Disease, Endocrinology, and Women’s Health
- Directed regulatory submissions and agency interactions (US/EU/Japan), inspection readiness, pediatric and post-approval studies
- Led advisory boards and KOL engagement
- Drove portfolio strategy, opportunity assessments, and clinical due diligence
- Fluent in English and Dutch; working knowledge of Italian, Spanish, French, and German